Company profile
Synthetic Biology for Human Health | Cells Reprogrammed | bit.bio
Using our opti-ox technology, we precisely, consistently and efficiently reprogram stem cells into any cell type at scale. Learn more!
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
SH01 | Transaction MzUxNjY5MTc1NGFkaXF6a2N4
Published 16 Apr 2026 15:32
Last confirmation statement made up date
Last accounts made up date
SH01 | Transaction MzQzNTExMTQ0OWFkaXF6a2N4
Published 10 Sep 2024 15:31
SH01 | Transaction MzQzNTExMTI1MmFkaXF6a2N4
Published 10 Sep 2024 15:29
SH01 | Transaction MzQzNTExMTA3NmFkaXF6a2N4
Published 10 Sep 2024 15:27
SH01 | Transaction MzQzNTExMDA2NmFkaXF6a2N4
Published 10 Sep 2024 15:18
SH01 | Transaction MzQzNTEwOTM2M2FkaXF6a2N4
Published 10 Sep 2024 15:11
AD01 | Transaction MzQyOTk1ODkwMWFkaXF6a2N4
Published 13 Sep 2024 07:52
Company registered at Companies House
1 Dec 2019 to 30 Nov 2022
Awaiting Public Project Summary
1 Aug 2017 to 31 Jul 2018
Expectations are increasing for regenerative medicine to address unmet clinical needs of devastating neurological diseases. Especially promising data are emerging from a US company’s pioneering clinical trial for patients with spinal cord injury in which human oligodendrocyte precursor cells (OPCs) are transplanted into the spinal cord. A major drawback o...
